Phibro Animal Health (NASDAQ:PAHC) Upgraded to “Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley raised their target price on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Barclays raised their target price on Phibro Animal Health from $20.00 to $22.00 and gave the company an “underweight” rating in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $21.00.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $21.25 on Friday. The firm’s fifty day moving average price is $22.57 and its 200 day moving average price is $22.56. Phibro Animal Health has a 1-year low of $12.05 and a 1-year high of $26.55. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.37. The firm has a market cap of $860.69 million, a price-to-earnings ratio of 44.27, a price-to-earnings-growth ratio of 0.45 and a beta of 0.58.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a net margin of 1.75% and a return on equity of 25.35%. On average, sell-side analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp acquired a new position in Phibro Animal Health in the 4th quarter valued at about $478,000. Public Employees Retirement System of Ohio acquired a new position in Phibro Animal Health in the 4th quarter valued at about $323,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Phibro Animal Health by 37.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,566 shares of the company’s stock valued at $1,314,000 after buying an additional 16,917 shares during the period. Virtus Fund Advisers LLC purchased a new stake in Phibro Animal Health in the 4th quarter valued at about $69,000. Finally, Virtus Investment Advisers Inc. grew its holdings in Phibro Animal Health by 103.4% in the 4th quarter. Virtus Investment Advisers Inc. now owns 49,504 shares of the company’s stock valued at $1,040,000 after buying an additional 25,160 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.